VP-16 and cisplatin as first-line therapy for small-cell lung cancer.

摘要: Thirty-one patients with small-cell lung cancer (SCLC) were treated VP-16 and cisplatin as first-line therapy. In the majority of cases an Adriamycin (Adria Laboratories, Columbus, Ohio) containing regimen was contraindicated because severe cardiac or hepatic disease. Eight who presented cerebral metastases also included in series. Eleven had limited disease (LD), 20 extensive (ED). Of 28 evaluable patients, 12 (43%) achieved a complete response (CR) partial (PR). Four (14%) either no progressed on treatment. The median duration for LD 39 weeks those ED, 26 weeks. survival time (MST) whole group responding (CR PR) 70 (range, to 181 + weeks), ED it 43 17 68 weeks). Gastrointestinal toxicity mild, but leukopenia thrombocytopenia common. There four febrile episodes during periods drug-induced neutropenia this led one treatment-related death. Nephrotoxicity occurred 15 required discontinuation two. These results compare favorably reports standard induction chemotherapy regimens provide further evidence activity SCLC.